– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...

The top 5 most-viewed videos of 2025 explored a range of topics, including data presented at major medical meetings, health ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Jeremy S. Abramson, MD, discusses 2-year results from the phase 3 STARGLO trial, which ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...

EMBARGOED: Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research that ...

A 2025 report cowritten by Iyengar that quoted federal data, said that the 5-year DLBCL survival is approximately 80% in ...

Roche’s Columvi (glofitamab), in combination with GemOx (gemcitabine and oxaliplatin), has demonstrated sustained survival benefit in patients with relapsed or refractory diffuse large B-cell lymphoma ...

Key Takeaways. TTP following R-CHOP is a strong prognostic factor for survival in R/R DLBCL, with shorter TTP linked to ...